徐瑞华 - 中山大学 - 肿瘤防治中心

个人简介

徐瑞华，医学博士（M.D., Ph.D.）。中山大学肿瘤防治中心院长、所长，华南肿瘤学国家重点实验室主任，肿瘤医学省部共建协同创新中心主任，国家新药（抗肿瘤药物）临床试验中心主任，教授，博士生导师，国务院政府特殊津贴专家，国家卫生计生突出贡献中青年专家

研究领域

长期从事消化道肿瘤个体化治疗领域及抗癌药物研究，在消化道肿瘤的转移与转归、化疗药物耐受及其机制和优化临床治疗方面具有国际领先的创新性成果，所治疗病患的5年生存率可达国际领先水平

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Xu RH#*, Wei W#, Krawczyk M#, Wang W#, Luo H#, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X, Zhang K*. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Materials. 2017 Nov;16(11):1155-1161. (IF: 38.9) 2. Xu RH#*, Muro K#*, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS*, Kim TW*. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology. 2018 May;19(5):660-671. (IF: 35.4) 3. Huiyan Luo#, Guoliang Xu#, Chaofeng Li#, Longjun He#, Linna Luo#, Zixian Wang#, Bingzhong Jing, Yishu Deng, Ying Jin, Yin Li, Bin Li, Wencheng Tan, Caisheng He, Sharvesh Raj Seeruttun, Qiubao Wu, Jun Huang, De-wang Huang, Bin Chen, Shao-bin Lin, Qin-ming Chen, Chu-ming Yuan, Hai-xin Chen, Heng-ying Pu, Feng Zhou, Yun He, Rui-hua Xu*. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncology. October 4, 2019 https://doi.org/10.1016/S1470-2045(19)30637-0 (IF: 35.4) 4. Feng Wang#, Qi Zhao#, Ying-NanWang, Jing Jin, Ming-Ming He, Ze-Xian Liu, Rui-Hua Xu*. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology. 2019;5(10):1504-1506. (IF: 22.4) 5. Wang DS#, Liu ZX#, Lu YX#, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW, Xu RH*. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2018 Sep 29. pii: gutjnl-2018-316522. (IF: 17.9) 6. Huiyan Luo#, Qi Zhao#, Wei Wei#, Lianghong Zheng#, Shaohua Yi#, Gen Li, Wenqiu Wang, Hui Sheng, Hengying Pu, Haiyu Mo, Zhixiang Zuo, Zexian Liu, Chaofeng Li, Chuanbo Xie, Zhaolei Zeng, Weimin Li, Xiaoke Hao, Yuying Liu, Sumei Cao, Wanli Liu, Sarah Gibson, Kang Zhang, Guoliang Xu, Rui-hua Xu. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction and 1 screening of colorectal cancer. Science Translational Medicine 12, eaax7533 (2020) (IF 17.2) 7. Chen DL#, Wang ZQ#, Zeng ZL#, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH*. Identification of miR-214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR1 expression. Hepatology，2014 Aug;60(2):598-609. (IF: 14.9) 8. Luo HY#, Li YH#, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW, Xu RH*. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol. 2016 Jun;27(6):1074-81. (IF: 14.2) 9. F. Wang#, X. L. Wei#, F. H. Wang#, N. Xu, L. Shen, G. H. Dai, X. L. Yuan, Y. Chen, S. J. Yang, J. H. Shi, X. C. Hu, X. Y. Lin, Q. Y. Zhang, J. F. Feng, Y. Ba, Y. P. Liu, W. Li, Y. Q. Shu, Y. Jiang, Q. Li, J. W. Wang, H.Wu, H. Feng, S. Yao & R. H. Xu*. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemorefractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 0: 1–8, 2019 doi:10.1093/annonc/mdz197 (IF: 14.2) 10. Ju HQ#, Lu YX#, Chen DL#, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ, Xu RH*. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. Journal of National Cancer Institute. 2018 Dec 8. doi: 10.1093/jnci/djy160. (IF: 10.2)